Geographic Atrophy in Dry-AMD
Although Retinitis Pigmentosa (RP) and Age-Related Macular Degeneration (AMD) have very different origins, both diseases are characterized by the degeneration of the photoreceptor cells of the retina of the patients and there is currently no cure for either condition.
AMD is a degenerative disorder driven by genetic and environmental factors. As its name implies, the
disease specifically affects the macula, which is the central retina, while the peripheral retina is spared.
Peripheral visual field is usually preserved even in the late stages of the disease. Central vision is essential toread, to perform precise tasks and recognize faces. Retention of peripheral vision allows the patient to maintain some degree of autonomy.
Macular degeneration typically occurs in patients over 55. The early form of AMD is called dry-AMD and
evolves over time to late AMD. Late AMD can take two forms, either wet-AMD or Geographic Atrophy (GA). We estimate that about 12 to 15 million patients suffer from AMD worldwide. However, late-stage AMD patients represent only a fraction of this population, of which about one third are patients suffering from GA. The effect of age on GA is significant, as its prevalence increases significantly in those older than 75, reaching 22% in the population over 90. We believe that there are more than 250,000 patients who are blind from GA in Europe and North America.
The following image illustrates the deterioration of normal vision to blindness in GA:
We believe that GS030 could be used for the treatment of GA. Once the proof of concept in man has been demonstrated from the results of our clinical trial in RP patients, we will start developing GS030 in GA patients. Our plan is to demonstrate that GS030 can be used to restore visual perception within the atrophic zone of the central retina.